Autologous hematopoietic stem cell transplantation with inadequate stem cell dose in patients with non-Hodgkin lymphoma

References

• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
   PubMed Web of Science ®Google Scholar
• Liu W, Liu J, Song Y, et al. Mortality of lymphoma and myeloma in China, 2004–2017: an observational study. J Hematol Oncol. 2019;12(1):22.
   PubMedGoogle Scholar
• Liu W, Liu J, Song Y, et al. Burden of lymphoma in China, 2006–2016: an analysis of the Global Burden of Disease Study 2016. J Hematol Oncol. 2019;12(1):115.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Kuhnt E, Trümper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12(11):1013–1022.
   PubMed Web of Science ®Google Scholar
• Yang Y, Zhu Y, Cao JZ, et al. Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study. Blood. 2015;126(12):1424–1432.
   PubMed Web of Science ®Google Scholar
• Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–1808.
   PubMed Web of Science ®Google Scholar
• Zhang JY, Briski R, Devata S, et al. Survival following salvage therapy for primary refractory peripheral T-cell lymphomas (PTCL). Am J Hematol. 2018;93(3):394–400.
   PubMed Web of Science ®Google Scholar
• National Health Commission of the People’s Republic of China. Chinese guidelines for diagnosis and treatment of malignant lymphoma 2018 (English version). Chin J Cancer Res. 2019;31:557–577.
   PubMed Web of Science ®Google Scholar
• Kharfan-Dabaja MA, Kumar A, Ayala E, et al. Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T cell and NK/t cell lymphomas: an international collaborative effort on behalf of the guidelines committee of the American Society for blood and marrow transplantation. Biol Blood Marrow Transplant. 2017;23(11):1826–1838.
   PubMed Web of Science ®Google Scholar
• Duong HK, Savani BN, Copelan E, et al. Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2014;20(9):1262–1273.
   PubMed Web of Science ®Google Scholar
• Giralt S, Costa L, Schriber J, et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant. 2014;20(3):295–308.
   PubMed Web of Science ®Google Scholar
• Oliansky DM, Czuczman M, Fisher RI, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review. Biol Blood Marrow Transplant. 2011;17(1):20–47.
   PubMed Web of Science ®Google Scholar
• Lekakis LJ, Moskowitz CH. The role of autologous stem cell transplantation in the treatment of diffuse large B-cell lymphoma in the Era of CAR-T cell therapy. Cell Therapy. Hemasphere. 2019;3(6):e295.
   PubMed Web of Science ®Google Scholar
• Jurinovic V, Metzner B, Pfreundschuh M, et al. Autologous stem cell transplantation for patients with early progression of follicular lymphoma: a follow-up study of 2 randomized trials from the german low grade lymphoma study group. Biol Blood Marrow Transplant. 2018;24(6):1172–1179.
   PubMed Web of Science ®Google Scholar
• Domingo-Domènech E, Boumendil A, Climent F, et al. Autologous hematopoietic stem cell transplantation for relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the lymphoma working party (LWP) of the EBMT. Bone Marrow Transplant. 2020;55(4):796–803.
   PubMed Web of Science ®Google Scholar
• Brammer JE, Chihara D, Poon LM, et al. Management of advanced and relapsed/refractory extranodal natural killer T-cell lymphoma: an analysis of stem cell transplantation and chemotherapy outcomes. Clin Lymphoma Myeloma Leuk. 2018;18(1):e41–e50.
   PubMed Web of Science ®Google Scholar
• Arboe B, Olsen MH, Gørløv JS, et al. Treatment intensity and survival in patients with relapsed or refractory diffuse large B-cell lymphoma in Denmark: a real-life population-based study. Clin Epidemiol. 2019;11:207–216.
   PubMed Web of Science ®Google Scholar
• Bellei M, Foss FM, Shustov AR, et al. The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. Haematologica. 2018;103(7):1191–1197.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Dingli D. How we manage autologous stem cell transplantation for patients with multiple myeloma. Blood. 2014;124(6):882–890.
   PubMed Web of Science ®Google Scholar
• Watts MJ, Linch DC. Optimisation and quality control of cell processing for autologous stem cell transplantation. Br J Haematol. 2016;175(5):771–783.
   PubMed Web of Science ®Google Scholar
• Watts MJ, Ings SJ, Balsa C, et al. Re-evaluation of progenitor thresholds and expectations for haematopoietic recovery based on an analysis of 810 autologous transplants: implications for quality assurance. Br J Haematol. 2016;175(4):673–676.
   PubMed Web of Science ®Google Scholar
• Jeyaraman P, Borah P, Dayal N, et al. Adequate engraftment with lower hematopoietic stem cell dose. Clin Lymphoma Myeloma Leuk. 2020;20(4):260–263.
   PubMed Web of Science ®Google Scholar
• Yamaguchi J, Chinen Y, Takimoto-Shimomura T, et al. Prediction of delayed platelet engraftment after autologous stem cell transplantation for B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2019;60(14):3434–3441.
   PubMed Web of Science ®Google Scholar
• Sorigue M, Sancho JM, Morgades M, et al. Relapse risk after autologous stem cell transplantation in patients with lymphoma based on CD34+ cell dose. Leuk Lymphoma. 2017;58(4):916–922.
   PubMed Web of Science ®Google Scholar
• Vaezi M, Shakouri M, Souri M, et al. The effects of lower CD34 yields after lowe dose G-CSF induction on long-term autologous stem cell transplantation outcome: a single center study. Transfus Apher Sci. 2018;57(2):265–271.
   PubMed Web of Science ®Google Scholar
• Wang H, Huang M, Zhao Y, et al. Recombinant human thrombopoietin promotes platelet engraftment and improves prognosis of patients with myelodysplastic syndromes and aplastic anemia after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2017;23(10):1678–1684.
   PubMed Web of Science ®Google Scholar
• Han TT, Xu LP, Liu DH, et al. Recombinant human thrombopoietin promotes platelet engraftment after haploidentical hematopoietic stem cell transplantation: a prospective randomized controlled trial. Ann Hematol. 2015;94(1):117–128.
   PubMed Web of Science ®Google Scholar
• Crawford J, Armitage J, Balducci L, et al. Myeloid growth factors. J Natl Compr Canc Netw. 2013;11(10):1266–1290.
   PubMed Web of Science ®Google Scholar